Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15548526 | 0.93 | KMT2A (0.49) | KMT2AALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL4079499 | 0.87 | TSHR (0.56) | KMT2AALDH1A1MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL15547890 | 0.86 | ALOX15 (0.47) | KMT2AALDH1A1MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL15547525 | 0.86 | PTGS2 (0.47) | KMT2AALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL24926171 | 0.85 | GABRA1 (0.48) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL24805097 | 0.85 | GABRA1 (0.48) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL16673227 | 0.85 | L3MBTL1 (0.57) | KMT2AALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL4092042 | 0.84 | ALDH1A1 (0.53) | KMT2AALDH1A1MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL15548877 | 0.83 | ALOX15 (0.50) | KMT2AALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL16672938 | 0.83 | KMT2A (0.46) | KMT2AALDH1A1MAPTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| CN-108473612-A | The manufacturing method of solid catalyst component for olefin polymerization, polymerization of olefines catalyst and olefin polymer | 东邦钛株式会社 | 2018-08-31 | — | — | CN | disclosed |
| CN-104250236-B | γ hydrocarbon oxygen sulfonylmethyl gamma butyrolactone, the synthetic method of δ hydrocarbon oxygen sulfonylmethyl δ valerolactone | 大连大学 | 2017-03-01 | — | — | CN | disclosed |
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | disclosed |
| EP-2237683-B1 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20130177688-A1 | Method of Flavoring | GIVAUDAN S.A. (CH) | 2013-07-11 | — | — | US | disclosed |
| WO-2009092176-A2 | METHOD OF FLAVORING | GIVAUDAN SA (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186138-A1 | Method of Flavoring | GIVAUDAN SA (CH) | 2009-07-23 | — | — | US | disclosed |
| CN-1812790-A | 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor | WYETH CORP (US) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186138-A1 | Method of Flavoring | TAS2R5, TAS2R50, TAS2R10 | KMT2A 1234/4885ALDH1A1 967/4885MAPT 4717/4885 |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | KMT2A 1547/4885ALDH1A1 1423/4885MAPT 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.